Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-TGFA)22.1Kor
• Allele Name: transgene insertion 22.1, Thomas R Korfhagen
• Allele ID: MGI:6275554
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-TGFA)22.1Kor/0	involves: 129 * C57BL/6	MGI:6275555
cx2	Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-TGFA)22.1Kor/0	involves: 129 * C57BL/6 * FVB/NJ	MGI:6275557

Genotype
MGI:6275555

cx1

• Allelic Composition: Tg(Scgb1a1-rtTA)1Jaw/0; Tg(tetO-TGFA)22.1Kor/0
• Genetic Background: involves: 129 * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

weight loss ( J:101255 )

• mice begin to progressively lose weight after 2 weeks of continuous doxycycline treatment and lose on average 15% of preinduction weight following 6 weeks of doxycycline; females tend to lose more weight than males

homeostasis/metabolism

increased hydroxyproline level ( J:101255 )

• hydroxyproline content in lung is increased over 70% in doxycyline treated mice

respiratory system

abnormal pulmonary acinus morphology ( J:101255 )

• enlarged distal air spaces are detected adjacent to areas of severe adventitial, peribronchial, or pleural fibrosis

pulmonary fibrosis ( J:101255 )

• mice develop progressive pulmonary fibrosis following doxycycline treatment, initially developing in the perivascular adventitia, peribronchial, and pleural regions but later extending into the interstitium

• fibrotic regions are composed of increased collagen, extracellular matrix, and cellular proliferation

• however, inflammatory cell infiltration is not seen in the fibrotic regions

Genotype
MGI:6275557

cx2

• Allelic Composition: Tg(Scgb1a1-rtTA)1Jaw/0; Tg(tetO-TGFA)22.1Kor/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/NJ

homeostasis/metabolism

increased hydroxyproline level ( J:240947 )

• hydroxyproline content is increased in the lungs of doxycycline treated mice

respiratory system

pulmonary fibrosis ( J:240947 )

• mice develop progressive pulmonary fibrosis in in the pleural and perivascular adventitia regions following doxycycline treatment

• however, 4 weeks after ending doxycycline treatment, fibrosis partially resolves

pulmonary interstitial fibrosis ( J:240947 )

• doxycycline treated mice show fibrosis extending from the subpleural and adventitial regions into the interstitium; these lesions grow in both number and volume throughout 7 weeks of doxycycline treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pulmonary fibrosis		DOID:3770		J:240947